Company Reports Q4 Revenue of $42.82M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Reports Q4 revenue $42.82M vs. $50.76M last year. "We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out the year," said Leslie Campbell, Interim Chief Executive Officer and President. "Throughout 2026, we focused on stabilizing our core business and strengthening the foundation for future long term value creation. We completed strategic, operational and technology initiatives that collectively reduced our cost structure and represent an important foundation for our future. We will continue to focus on operational excellence, driving sustainable long-term results, and delivering value for shareholders. We intend to do this in part through improved customer retention by leveraging our operational improvements, and also by expanding our market footprint through B2B relationships utilizing our membership programs as well as our white-label pharmacy fulfillment services like our recently announced Master Services Agreement with Rural King."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PETS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PETS
About PETS
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PetMed Express Reports Financial and Operational Improvements
- Regulatory Compliance Restored: PetMed Express successfully regained critical regulatory compliance and improved internal controls in fiscal year 2026, remediating three previously disclosed material weaknesses, thereby laying a foundation for future sustainable growth.
- Sales Fluctuations: While the fourth quarter net sales marked the first sequential increase since fiscal year 2024, the overall net sales for the year declined by 21.1%, indicating that the ongoing decrease in prescription medication sales negatively impacted total revenue.
- Cost Reduction Success: The company exited underperforming vendor relationships, yielding approximately $6.1 million in annualized savings, which not only improved cost structure but also enhanced operational efficiency and customer experience.
- Clear Strategic Direction: Looking ahead to fiscal year 2027, PetMed Express plans to focus on operational excellence, customer retention, and market expansion, aiming to drive long-term sustainable shareholder value through B2B relationships and improvements in technology and infrastructure.
See More
PetMed Express (PETS) Q4 2026 Earnings Transcript
See More
PetMed Express Q4 Fiscal 2026 Earnings Call Insights
- Sales Decline: PetMed Express reported net sales of $179 million for fiscal year 2026, reflecting a 21.1% year-over-year decline primarily due to reduced prescription medication sales, although the revenue decline slowed to 15.6% in Q4 compared to the previous year.
- Cost Reduction Success: The company made significant progress in cost-cutting efforts, exiting underperforming vendor relationships in the second half of the year, which is expected to yield approximately $6.1 million in annualized savings, indicating effective financial management.
- Technology Infrastructure Upgrade: The successful implementation of a new ERP system, fraud prevention system, and call center technology has strengthened operational capabilities, aiming to enhance customer experience and significantly reduce operational risks moving forward.
- Independent Operation Decision: The Board opted not to proceed with two unsolicited acquisition proposals priced between $4 and $4.25 per share, choosing to continue operating as an independent publicly traded company, which reflects confidence in the company's long-term strategy.
See More
PetMed Express Reports Wider Loss Amid Revenue Decline
- Wider Loss Reported: PetMed Express reported a fiscal fourth-quarter loss of $0.19 per share, which, while an improvement from last year's $0.56 loss, still missed expectations by $0.01, indicating ongoing profitability challenges for the company.
- Significant Revenue Decline: The company's net sales fell by 15.6% to $42.8 million, primarily driven by a decrease in prescription medication sales, a trend that could negatively impact future market share and competitive positioning.
- Deteriorating Cash Flow: By fiscal year-end, PetMed Express's cash and cash equivalents plummeted nearly two-thirds to $21.4 million, and net cash from operating activities swung to a $28.4 million outflow from a $4.7 million inflow a year earlier, reflecting increasing liquidity risks for the company.
- Rejection of Acquisition Offers: Despite receiving a $4.25 per share acquisition offer from Cardone Ventures, PetMed Express has opted to continue operating as an independent publicly traded company, a decision that may affect investor confidence in the company's future prospects.
See More
PetMed Express Q4 Earnings Miss Expectations Amid Acquisition Proposals
- Earnings Report Disappointment: PetMed Express reported a Q4 GAAP EPS of -$0.19, missing expectations by $0.01, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company's Q4 revenue of $42.82 million represents a 15.6% year-over-year decrease, reflecting weak market demand and intensified competition, which could lead to uncertainty in future growth prospects.
- Acquisition Proposals Rejected: The Board determined it is in the best interest of the company not to proceed with publicly announced acquisition proposals, indicating a commitment to operate as an independent publicly traded entity, which may affect shareholder perceptions of the company's strategic direction.
- Potential Acquisition Price Range: In December 2025, the company received two unsolicited, non-binding acquisition proposals with offers ranging from $4.00 to $4.25 per share, demonstrating market interest in its assets, although no transactions were finalized.
See More
Major Earnings Reports Expected After Tuesday's Close
- Earnings Release Companies: Major companies expected to report earnings after Tuesday's close include Palo Alto Networks (PANW), Ulta Beauty (ULTA), GitLab (GTLB), and Yext (YEXT), all of which hold significant market positions in their respective sectors, drawing keen investor interest.
- Market Reaction Expectations: Given the influence of these companies in cybersecurity, beauty, software development, and digital marketing, the market's reaction to their earnings reports could impact overall investment sentiment in related industries, especially in the current economic climate.
- Other Earnings Releases: In addition to the major companies, others like PETS and SPWH are also slated to release earnings after Tuesday's close, potentially providing investors with additional market dynamics and investment opportunities.
- Earnings Season Calendar: Seeking Alpha offers a comprehensive earnings season calendar, allowing investors to access more information to better navigate market trends and make informed investment decisions.
See More
PetMed Express Reports Financial and Operational Improvements
- Regulatory Compliance Restored: PetMed Express successfully regained critical regulatory compliance and improved internal controls in fiscal year 2026, remediating three previously disclosed material weaknesses, thereby laying a foundation for future sustainable growth.
- Sales Fluctuations: While the fourth quarter net sales marked the first sequential increase since fiscal year 2024, the overall net sales for the year declined by 21.1%, indicating that the ongoing decrease in prescription medication sales negatively impacted total revenue.
- Cost Reduction Success: The company exited underperforming vendor relationships, yielding approximately $6.1 million in annualized savings, which not only improved cost structure but also enhanced operational efficiency and customer experience.
- Clear Strategic Direction: Looking ahead to fiscal year 2027, PetMed Express plans to focus on operational excellence, customer retention, and market expansion, aiming to drive long-term sustainable shareholder value through B2B relationships and improvements in technology and infrastructure.
See More
PetMed Express (PETS) Q4 2026 Earnings Transcript
See More
PetMed Express Q4 Fiscal 2026 Earnings Call Insights
- Sales Decline: PetMed Express reported net sales of $179 million for fiscal year 2026, reflecting a 21.1% year-over-year decline primarily due to reduced prescription medication sales, although the revenue decline slowed to 15.6% in Q4 compared to the previous year.
- Cost Reduction Success: The company made significant progress in cost-cutting efforts, exiting underperforming vendor relationships in the second half of the year, which is expected to yield approximately $6.1 million in annualized savings, indicating effective financial management.
- Technology Infrastructure Upgrade: The successful implementation of a new ERP system, fraud prevention system, and call center technology has strengthened operational capabilities, aiming to enhance customer experience and significantly reduce operational risks moving forward.
- Independent Operation Decision: The Board opted not to proceed with two unsolicited acquisition proposals priced between $4 and $4.25 per share, choosing to continue operating as an independent publicly traded company, which reflects confidence in the company's long-term strategy.
See More
PetMed Express Reports Wider Loss Amid Revenue Decline
- Wider Loss Reported: PetMed Express reported a fiscal fourth-quarter loss of $0.19 per share, which, while an improvement from last year's $0.56 loss, still missed expectations by $0.01, indicating ongoing profitability challenges for the company.
- Significant Revenue Decline: The company's net sales fell by 15.6% to $42.8 million, primarily driven by a decrease in prescription medication sales, a trend that could negatively impact future market share and competitive positioning.
- Deteriorating Cash Flow: By fiscal year-end, PetMed Express's cash and cash equivalents plummeted nearly two-thirds to $21.4 million, and net cash from operating activities swung to a $28.4 million outflow from a $4.7 million inflow a year earlier, reflecting increasing liquidity risks for the company.
- Rejection of Acquisition Offers: Despite receiving a $4.25 per share acquisition offer from Cardone Ventures, PetMed Express has opted to continue operating as an independent publicly traded company, a decision that may affect investor confidence in the company's future prospects.
See More
PetMed Express Q4 Earnings Miss Expectations Amid Acquisition Proposals
- Earnings Report Disappointment: PetMed Express reported a Q4 GAAP EPS of -$0.19, missing expectations by $0.01, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company's Q4 revenue of $42.82 million represents a 15.6% year-over-year decrease, reflecting weak market demand and intensified competition, which could lead to uncertainty in future growth prospects.
- Acquisition Proposals Rejected: The Board determined it is in the best interest of the company not to proceed with publicly announced acquisition proposals, indicating a commitment to operate as an independent publicly traded entity, which may affect shareholder perceptions of the company's strategic direction.
- Potential Acquisition Price Range: In December 2025, the company received two unsolicited, non-binding acquisition proposals with offers ranging from $4.00 to $4.25 per share, demonstrating market interest in its assets, although no transactions were finalized.
See More
Major Earnings Reports Expected After Tuesday's Close
- Earnings Release Companies: Major companies expected to report earnings after Tuesday's close include Palo Alto Networks (PANW), Ulta Beauty (ULTA), GitLab (GTLB), and Yext (YEXT), all of which hold significant market positions in their respective sectors, drawing keen investor interest.
- Market Reaction Expectations: Given the influence of these companies in cybersecurity, beauty, software development, and digital marketing, the market's reaction to their earnings reports could impact overall investment sentiment in related industries, especially in the current economic climate.
- Other Earnings Releases: In addition to the major companies, others like PETS and SPWH are also slated to release earnings after Tuesday's close, potentially providing investors with additional market dynamics and investment opportunities.
- Earnings Season Calendar: Seeking Alpha offers a comprehensive earnings season calendar, allowing investors to access more information to better navigate market trends and make informed investment decisions.
See More
